share_log

6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

6-K:外国发行人报告
美股SEC公告 ·  2024/10/30 06:46

Moomoo AI 已提取核心信息

NeuroSense Therapeutics has reached a significant milestone in its PARADIGM Phase 2b ALS clinical trial with the completion of 18-month dosing, marked by the Last Patient Last Visit. The company is now preparing to report comprehensive top-line clinical results from the full study in early December 2024.The trial evaluates PrimeC as a potential treatment for ALS (Amyotrophic Lateral Sclerosis). This development represents a crucial step in assessing the safety and efficacy of PrimeC in targeting ALS, though outcomes remain subject to final analysis and regulatory review by the FDA and Health Canada.
NeuroSense Therapeutics has reached a significant milestone in its PARADIGM Phase 2b ALS clinical trial with the completion of 18-month dosing, marked by the Last Patient Last Visit. The company is now preparing to report comprehensive top-line clinical results from the full study in early December 2024.The trial evaluates PrimeC as a potential treatment for ALS (Amyotrophic Lateral Sclerosis). This development represents a crucial step in assessing the safety and efficacy of PrimeC in targeting ALS, though outcomes remain subject to final analysis and regulatory review by the FDA and Health Canada.
NeuroSense Therapeutics在其PARADIGm 20亿ALS临床试验中达到了一个重要里程碑,完成了18个月的给药,标志着最后一位患者的最后一次访视。该公司现在正在准备在2024年12月初报告整个研究的全面顶线临床结果。该试验评估了PrimeC作为潜在的ALS(肌萎缩侧索硬化症)治疗方案。这一进展代表了评估PrimeC在靶向ALS方面安全性和有效性的重要步骤,尽管结果仍待FDA和加拿大卫生部门的最终分析和监管审查。
NeuroSense Therapeutics在其PARADIGm 20亿ALS临床试验中达到了一个重要里程碑,完成了18个月的给药,标志着最后一位患者的最后一次访视。该公司现在正在准备在2024年12月初报告整个研究的全面顶线临床结果。该试验评估了PrimeC作为潜在的ALS(肌萎缩侧索硬化症)治疗方案。这一进展代表了评估PrimeC在靶向ALS方面安全性和有效性的重要步骤,尽管结果仍待FDA和加拿大卫生部门的最终分析和监管审查。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息